U.S. Leukemia Therapeutics Market (2025 - 2033) Size, Share & Trends Analysis Report By Type (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), By Treatment, By Distribution Channels, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Type
                        1.2.2. Treatment
                        1.2.3. Distribution Channels
                    1.3. Estimates and Forecast Timeline
                    1.4. Research Methodology
                    1.5. Information Procurement
                        1.5.1. Purchased Database
                        1.5.2. GVR’s Internal Database
                        1.5.3. Secondary Sources
                        1.5.4. Primary Research
                    1.6. Information Analysis
                        1.6.1. Data Analysis Models
                    1.7. Market Formulation & Data Visualization
                    1.8. Model Details
                        1.8.1. Commodity Flow Analysis
                    1.9. List of Secondary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Leukemia Therapeutics Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. Business Environment Analysis
                        3.3.1. Industry Analysis - Porter’s Five Forces Analysis
                            3.3.1.1. Supplier Power
                            3.3.1.2. Buyer Power
                            3.3.1.3. Substitution Threat
                            3.3.1.4. Threat of New Entrants
                            3.3.1.5. Competitive Rivalry
                        3.3.2. PESTLE Analysis
                        3.3.3. Pipeline Analysis
                        3.3.4. Patent Expiry Analysis
                        3.3.5. Pricing Analysis
Chapter 4. U.S. Leukemia Therapeutics Market: Type Business Analysis
                    4.1. Type Market Share, 2024 & 2033
                    4.2. Type Segment Dashboard
                    4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
                    4.4. Chronic Myeloid Leukemia (CML)
                        4.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
                    4.5. Chronic Lymphocytic Leukemia (CLL)
                        4.5.1. Chronic Lymphocytic Leukemia (CLL) Market, 2021 - 2033 (USD Million)
                    4.6. Acute Lymphocytic Leukemia (ALL)
                        4.6.1. Acute Lymphocytic Leukemia (ALL) Market, 2021 - 2033 (USD Million)
                    4.7. Acute Myeloid Leukemia (AML)
                        4.7.1. Acute Myeloid Leukemia (AML) Market, 2021 - 2033 (USD Million)
                    4.8. Others
                        4.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. U.S. Leukemia Therapeutics Market: Treatment Business Analysis
                    5.1. Treatment Market Share, 2024 & 2033
                    5.2. Treatment Segment Dashboard
                    5.3. Market Size & Forecasts and Trend Analysis, by treatment, 2021 to 2033 (USD Million)
                    5.4. Chemotherapy
                        5.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
                    5.5. Targeted Therapy
                        5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
                    5.6. Immunotherapy
                        5.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
                    5.7. Others
                        5.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. U.S. Leukemia Therapeutics Market: Distribution Channels Business Analysis
                    6.1. Distribution Channels Market Share, 2024 & 2033
                    6.2. Distribution Channels Segment Dashboard
                    6.3. Market Size & Forecasts and Trend Analysis, by distribution channels, 2021 to 2033 (USD Million)
                    6.4. Hospital Pharmacy
                        6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
                    6.5. Retail Pharmacy
                        6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
                    6.6. Others
                        6.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Participant Overview
                    7.2. Company Market Position Analysis
                    7.3. Company Categorization
                    7.4. Strategy Mapping
                    7.5. Company Profiles/Listing
                        7.5.1. Novartis
                            7.5.1.1. Overview
                            7.5.1.2. Financial Performance
                            7.5.1.3. Product Benchmarking
                            7.5.1.4. Strategic Initiatives
                        7.5.2. Roche / Genentech
                            7.5.2.1. Overview
                            7.5.2.2. Financial Performance
                            7.5.2.3. Product Benchmarking
                            7.5.2.4. Strategic Initiatives
                        7.5.3. AbbVie
                            7.5.3.1. Overview
                            7.5.3.2. Financial Performance
                            7.5.3.3. Product Benchmarking
                            7.5.3.4. Strategic Initiatives
                        7.5.4. Bristol-Myers Squibb (BMS)
                            7.5.4.1. Overview
                            7.5.4.2. Financial Performance
                            7.5.4.3. Product Benchmarking
                            7.5.4.4. Strategic Initiatives
                        7.5.5. Pfizer
                            7.5.5.1. Overview
                            7.5.5.2. Financial Performance
                            7.5.5.3. Product Benchmarking
                            7.5.5.4. Strategic Initiatives
                        7.5.6. Amgen
                            7.5.6.1. Overview
                            7.5.6.2. Financial Performance
                            7.5.6.3. Product Benchmarking
                            7.5.6.4. Strategic Initiatives
                        7.5.7. Johnson & Johnson (Janssen)
                            7.5.7.1. Overview
                            7.5.7.2. Financial Performance
                            7.5.7.3. Product Benchmarking
                            7.5.7.4. Strategic Initiatives
                        7.5.8. Gilead Sciences (Kite Pharma)
                            7.5.8.1. Overview
                            7.5.8.2. Financial Performance
                            7.5.8.3. Product Benchmarking
                            7.5.8.4. Strategic Initiatives
                        7.5.9. AstraZeneca
                            7.5.9.1. Overview
                            7.5.9.2. Financial Performance
                            7.5.9.3. Product Benchmarking
                            7.5.9.4. Strategic Initiatives
                        7.5.10. Sanofi
                            7.5.10.1. Overview
                            7.5.10.2. Financial Performance
                            7.5.10.3. Product Benchmarking
                            7.5.10.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. leukemia therapeutics market, by Type, 2021-2033, (USD Million)
Table 4 U.S. leukemia therapeutics market, by treatment, 2021-2033, (USD Million)
Table 5 U.S. leukemia therapeutics market, by distribution channels, 2021-2033, (USD Million) 

List of Figures

Fig. 1 U.S. leukemia therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 U.S. leukemia therapeutics market dynamics
Fig. 12 U.S. leukemia therapeutics market: Porter’s five forces analysis
Fig. 13 U.S. leukemia therapeutics market: PESTLE analysis
Fig. 14 Type market, 2021 - 2033 (USD Million)
Fig. 15 Chronic Myeloid Leukemia (CML) market, 2021 - 2033 (USD Million)
Fig. 16 Chronic Lymphocytic Leukemia (CLL) market, 2021 - 2033 (USD Million)
Fig. 17 Acute Lymphocytic Leukemia (ALL) market, 2021 - 2033 (USD Million)
Fig. 18 Acute Myeloid Leukemia (AML) market, 2021 - 2033 (USD Million)
Fig. 19 Others market, 2021 - 2033 (USD Million)
Fig. 20 Treatment market, 2021 - 2033 (USD Million)
Fig. 21 Chemotherapy market, 2021 - 2033 (USD Million)
Fig. 22 Targeted Therapy market, 2021 - 2033 (USD Million)
Fig. 23 Immunotherapy market, 2021 - 2033 (USD Million)
Fig. 24 Others market, 2021 - 2033 (USD Million)
Fig. 25 Distribution Channels market, 2021 - 2033 (USD Million)
Fig. 26 Hospital Pharmacy market, 2021 - 2033 (USD Million)
Fig. 27 Retail Pharmacy market, 2021 - 2033 (USD Million)
Fig. 28 Others market, 2021 - 2033 (USD Million)
Fig. 29 Company categorization
Fig. 30 Company market position analysis
Fig. 31 Strategic framework